Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Use of Angiotensin-(1-7) in COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04633772
Recruitment Status : Recruiting
First Posted : November 18, 2020
Last Update Posted : November 23, 2020
Sponsor:
Collaborators:
Federal University of Minas Gerais
Angitec
Fonds Erasme pour la Recherche Medicale
Information provided by (Responsible Party):
Erasme University Hospital

Brief Summary:
The renin-angiotensin system (RAS) has a relevant role in COVID-19, as the virus will enter host's cells via the angiotensin-converting enzyme 2 (ACE2); RAS disequilibrium might also play a key role in the modulation of the inflammatory response that characterizes the lung involvement. Angiotensin-(1-7) is a peptide that could be altered in COVID-19 patient and its supplementation may potentially helpful in this setting.

Condition or disease Intervention/treatment Phase
Infection, Coronavirus Respiratory Failure Drug: Angiotensin-(1-7) Drug: Placebo Phase 1 Phase 2

Detailed Description:
A novel Coronavirus (SARS-CoV-2) described in late 2019 in Wuhan, China, has led to a pandemic and to a specific coronavirus-related disease (COVID-19), which is mainly characterized by a respiratory involvement. While researching for a vaccine has been started, effective therapeutic solutions are urgently needed to face this threaten. The renin-angiotensin system (RAS) has a relevant role in COVID-19, as the virus will enter host's cells via the angiotensin-converting enzyme 2 (ACE2); RAS disequilibrium might also play a key role in the modulation of the inflammatory response that characterizes the lung involvement. Angiotensin-(1-7) is a peptide that could be altered in COVID-19 patient and it may potentially improve respiratory function in this setting. This a randomized, controlled, investigator-initiated Phase I/Phase II trial is conceived to test the safety and the efficacy of intravenous angiotensin-(1-7) infusion in COVID-19 patients with severe pneumonia admitted to the intensive care unit (ICU). The first phase of the study, with a limited number of patients (n=30) will serve to confirm the safety of the intravenous infusion of the drug by observing the incidence of the adverse events (phase I, open label). In a second phase of the study, conducted in a double-blind manner and including a larger cohort of patients (n=100, Phase II), patients will be randomly assigned to receive either an Angiotensin-(1-7) infusion or placebo. The primary endpoint of the study will be the number of supplemental oxygen-free days by day 28. Secondary outcomes will include length of hospital stay, ICU and hospital free days, ICU and hospital mortality, need for mechanical ventilation, weaning time from mechanical ventilation if intubated, secondary infections, vasopressor needs, changes in PaO2 / FiO2, incidence of deep vein thrombosis, changes in inflammatory markers, plasma levels of angiotensin II and angiotensin (1-7) and radiological findings.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 130 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized Clinical Trial Phase I/II for the Use of Angiotensin-(1-7) in the Treatment of Severe Infection by Sars-CoV-2
Actual Study Start Date : August 5, 2020
Estimated Primary Completion Date : February 1, 2021
Estimated Study Completion Date : February 28, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: Placebo Drug: Placebo
NaCl 0.9%

Experimental: Angiotensin-(1-7) Drug: Angiotensin-(1-7)
Intravenous supplementation of Angiotensin-(1-7)




Primary Outcome Measures :
  1. supplemental oxygen-free days (SOFDs) [ Time Frame: 28 days ]
    28 - x, where x = number of days on which the patient is released from supplemental oxygen therapy after start


Secondary Outcome Measures :
  1. Hospital length of stay [ Time Frame: through study completion, on average 60 days ]
    Hospital length of stay

  2. ventilator free days [ Time Frame: 28 days ]
    composite outcome of mortality and necessity of mechanical ventilation

  3. ICU free days [ Time Frame: through study completion, on average 40 days ]
    number of days free from intensive care unit

  4. RAS effectors levels [ Time Frame: Baseline, 3 and 24 hours after randomization and 72 hours after randomization ]
    Ang II and Ang-(1-7) circulating levels using mass spectrometry

  5. CT scan findings [ Time Frame: through study completion, on average 30 days ]
    CT scan evolutions compared to baseline including findings compatible with late pulmonary fibrosis.

  6. Changes in inflammatory markers: C reactive protein [ Time Frame: through study completion, on average 30 days ]
    C-reactive protein levels daily measurements

  7. Changes in clinical state: vasopressors usage [ Time Frame: through study completion, on average 30 days ]
    use of vasopressors during hospitalization

  8. Chest X ray findings [ Time Frame: through study completion, on average 30 days ]
    Chest X-ray modifications until hospital discharge

  9. Changes in inflammatory markers: chemokines [ Time Frame: Baseline, 3 and 24 hours after randomization and 72 hours after randomization ]
    pro-inflammatory chemokine levels (IL-1/IL-6) at baseline day 3 and 7

  10. Changes in inflammatory markers: troponin [ Time Frame: Baseline, 3 and 24 hours after randomization and 72 hours after randomization ]
    Troponin plasmatic levels

  11. Changes in thrombotic markers: D-Dimer [ Time Frame: Baseline, 3 and 24 hours after randomization and 72 hours after randomization ]
    D-Dimer

  12. Changes in clinical state: secondary infections [ Time Frame: through study completion, on average 30 days ]
    Secondary infections recorded during hospitalization

  13. Changes in clinical state: deep venous thrombosis [ Time Frame: through study completion, on average 30 days ]
    deep venous thrombosis recorded during hospitalization



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   17 Years to 81 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Admission to the Intensive Care Unit with severe pneumonia criteria (clinical signs of pneumonia + one of the following criteria: respiratory rate greater than 30/minute; signs of respiratory effort, SatO2 < 90% in room air);
  • COVID-19 confirmed or highly suspicious (positive contact or suggestive image)

Exclusion Criteria:

  • Diagnosed with cancer (at any stage);
  • Hemodynamic instability (need for vasopressors);
  • Pregnant women; Immunocompromised patients;
  • Palliative Care;
  • Inclusion in any other interventionist study;
  • Heart failure as a predominant cause of acute respiratory failure;
  • Decompensated liver cirrhosis;
  • HIV +;
  • Dialysis;
  • Home / long-term oxygen therapy;
  • Idiopathic pulmonary fibrosis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04633772


Contacts
Layout table for location contacts
Contact: Robson AS Santos +55(31)987762956 santos@icb.ufmg.br
Contact: Ana Luiza Martins Valle +55(31)97654162 anavalle9@icloud.com

Locations
Layout table for location information
Brazil
Hospital Eduardo de Menezes Recruiting
Belo Horizonte, Minas Gerais, Brazil, 30190-081
Contact: Ana Luiza Martins Valle    +55(31)97654162    anavalle9@icloud.com   
Hospital Mater Dei Recruiting
Belo Horizonte, Minas Gerais, Brazil, 31270-910
Contact: Ana Luiza Martins Valle    +55(31)97654162      
Contact: anavalle9@icloud.com         
Sponsors and Collaborators
Erasme University Hospital
Federal University of Minas Gerais
Angitec
Fonds Erasme pour la Recherche Medicale
Investigators
Layout table for investigator information
Principal Investigator: Robson AS Santos Angitex
Principal Investigator: Ana Martins Valle Federal University of Minas Gerais
Principal Investigator: Filippo Annoni Hôpital Erasme
Layout table for additonal information
Responsible Party: Erasme University Hospital
ClinicalTrials.gov Identifier: NCT04633772    
Other Study ID Numbers: RBR-35734p
First Posted: November 18, 2020    Key Record Dates
Last Update Posted: November 23, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Erasme University Hospital:
angiotensin-(1-7)
ARDS
renin angiotensin system
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Coronavirus Infections
Respiratory Insufficiency
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Virus Diseases
Respiration Disorders
Respiratory Tract Diseases
Angiotensin I (1-7)
Antihypertensive Agents
Vasodilator Agents